Related Experiment Video
Updated: Jun 18, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells
Joshua D O'Donnell1, Rebecca J Linger, Patricia A Kruk
1Department of Pathology and Cell Biology, College of Medicine, University of South Florida,Tampa, FL 33612, USA.
Objective:
Aggressive clinical course and difficult detection of ovarian cancer are major challenges to improving patient survival and necessitate avid investigation into more effective therapeutic approaches. Understanding early molecular and pathological changes in high risk patients, such as BRCA1 mutation carriers, can provide candidates for molecular profiling and novel targets for effective therapies.
Methods:
Using a culture model system for normal human ovarian surface epithelial cells with and without the BRCA1 185delAG frameshift mutation for the truncated protein product, BRAt, we investigated the role of BRAt in enhanced chemosensitivity. We used MTS, Western immunoblot, semi-quantitative RT-PCR, luciferase reporter and siRNA assays, to identify novel downstream targets of BRAt that promote apoptosis following chemotherapeutic treatment.
Results:
We identified maspin as a novel downstream target of BRAt. BRAt increases maspin expression with preferential nuclear localization of maspin. Further, Brat-mediated maspin expression is transcriptionally regulated through an AP1 site within the (-520) to (-297) region of the promoter. Lastly, BRAt, enhances chemosensitivity in normal ovarian surface epithelial cells through c-Jun by a mechanism that may involve maspin.
Conclusions:
BRAt-mediated enhanced chemosensitivity correlates clinically with enhanced chemotherapeutic response in BRCA1 mutation carriers. BRAt-mediated maspin expression also correlates with improved prognostic outlook for ovarian tumors with high levels of nuclear maspin. Consequently, understanding early genotypic and phenotypic changes in the context of high risk disease may provide a better understanding of the mechanism of mutation-associated ovarian cancer and provide new targets for therapeutic intervention.
Insights
BRCA1 mutation carriers with truncated BRAt protein show enhanced chemosensitivity. This involves increased maspin expression, a potential therapeutic target for ovarian cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian cancer presents significant challenges due to its aggressive nature and late detection.
- Identifying early molecular changes in high-risk individuals, like BRCA1 mutation carriers, is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the role of the truncated BRCA1 protein (BRAt) in enhanced chemosensitivity.
- To identify novel downstream targets of BRAt that promote apoptosis after chemotherapy.
Main Methods:
- Utilized a cell culture model of normal human ovarian surface epithelial cells with and without the BRCA1 185delAG mutation.
- Employed MTS, Western immunoblot, RT-PCR, luciferase reporter, and siRNA assays to identify BRAt targets.
Main Results:
- Maspin was identified as a novel downstream target of BRAt, with BRAt increasing maspin expression and nuclear localization.
- BRAt-mediated maspin expression is transcriptionally regulated via an AP1 site in the promoter region.
- BRAt enhances chemosensitivity in ovarian cells through c-Jun, potentially involving maspin.
Conclusions:
- BRAt-mediated chemosensitivity correlates with improved chemotherapeutic response in BRCA1 mutation carriers.
- High nuclear maspin levels correlate with an improved prognostic outlook in ovarian tumors.
- Understanding early molecular and pathological changes in high-risk ovarian cancer can reveal new therapeutic targets.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
Negative Regulator Molecules
The Ras Gene
Ras is a superfamily...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:

